Sandoz Sees Market Opening Up In China
As China’s government raises quality standards for generics, Sandoz views the local market as promising, according to the Novartis division’s head, Richard Francis.
You may also be interested in...
Sandoz Will Consider Local Partnerships In China
As it builds a portfolio in the Chinese market, which is increasingly focused on high-quality products, Sandoz is considering teaming up with local players for certain drugs.
Sandoz’ Unique Chinese Approval Paves The Way For Tender Access
Sandoz says a first-of-its-kind Chinese approval for generic rosuvastatin will open the door for the firm to participate in local tenders.
Autonomous Sandoz Set To Be Tighter And Leaner
With an optimized manufacturing base, a narrower geographic footprint, and a tighter portfolio focus on differentiated biosimilars and hard-to-make generics, Novartis believes a more autonomous Sandoz division can remain an “integral part” of the Swiss group.